International Urology and Nephrology

, Volume 45, Issue 5, pp 1453–1461

The burden of anti-HCV genotye-4 positivity in renal transplant recipients: 8 years follow-up

Nephrology - Original Paper


Whether renal transplant recipients with anti-HCV antibodies positivity and normal liver function tests within the first year after transplantation have different morbidity and mortality and graft failure compared to anti-HCV-negative recipients remains controversial. In this retrospective study, on 411 renal transplant recipients, we analyzed grafts morbidity, survival, and liver function tests over a period of 8 years. Patients were stratified according to their anti-HCV antibody status 1 year after transplantation into anti-HCV-positive and HCV-negative patients. The presence of normal liver function tests was mandatory at inclusion. All patients received the same immunosuppressive protocol consisting of cyclosporine A, mycophenolate mofetil and steroids. One year after transplantation, 137 patients were anti-HCV negative (33 %) while the rest 274 (67 %) were positive. At 5 years of follow-up, the study population consisted of 205 patients (71 patients, 35 % with anti-HCV negativity, and 134, 65 % with positivity). At the end of the study, only 144 patients were followed up (43 patients, 30 % with negative anti-HCV and 101 patients, 70 %, with positivity). We found that graft survival was not different between both groups. Moreover, serum creatinine showed a trend to be lower in HCV-positive patients compared to negative group although difference was not statistically significant. The number of graft loss was not different between both groups. Moreover, there was no difference between both groups as regards prevalence of acute rejection, diabetes mellitus, hypertension, CMV disease and proteinuria. We can conclude that anti-HCV positivity for 8 years in patients with normal liver function tests at 1 year does not impact graft morbidity and patient survival.


Hepatitis C Renal transplant Graft morbidity Patient survival 


  1. 1.
    NIH Consensus Statement on Management of Hepatitis C (2002) NIH Consens State Sci Statements 19(3):1–46Google Scholar
  2. 2.
    Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B et al (1998) Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. international committee on virus taxonomy. Arch Virol 143:2493–2503PubMedCrossRefGoogle Scholar
  3. 3.
    Hnatyszyn HJ (2005) Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther 10:1–11PubMedGoogle Scholar
  4. 4.
    World Health Organization (2012) Hepatitis C. WHO fact sheet 164. Available at: Accessed 17 Nov 2012
  5. 5.
    Nguyen MH, Keeffe EB (2005) Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 3(Suppl 2):S97–S101PubMedCrossRefGoogle Scholar
  6. 6.
    Egyptian Ministry of Health (2007) Egyptian Ministry of Health Annual Report. Available at DocLib4/NHA report.pdf. Accessed 17 2012
  7. 7.
    Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S et al (2000) Hepatitis C virus (HCV) infection in a community in the Nile delta: population description and HCV prevalence. Hepatology 32:111–115PubMedCrossRefGoogle Scholar
  8. 8.
    Legendre C, Garrigue V, Le Bihan C et al (1998) Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 65:667–670PubMedCrossRefGoogle Scholar
  9. 9.
    Morales JM, Campistol JM, Dominguez-Gil B (2002) Hepatitis C virus infection and kidney transplantation. Semin Nephrol 22:365–374PubMedGoogle Scholar
  10. 10.
    Soliman AR, Abd Elaziz MM, El lawindi MI (2013) Evaluation of an isolation program of hepatitis C virus infected hemodialysis patients in some hemodialysis centers in Egypt. ISRN Nephrol, vol 2013, article ID 395467.
  11. 11.
    Simmonds P, Holmes EC, Cha T-A, Chan SW, McOmish F, Irvine B et al (1993) Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74:2391–2399PubMedCrossRefGoogle Scholar
  12. 12.
    Pybus O, Drummond A, Nakano T, Robertson BH, Rambaut A (2003) The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol 20:381–387PubMedCrossRefGoogle Scholar
  13. 13.
    Tanaka Y, Agha S, Saudy N, Kurbanov F, Orito E, Kato T et al (2004) Exponential spread of hepatitis C virus genotype 4a in Egypt. J Mol Evol 58:191–195PubMedCrossRefGoogle Scholar
  14. 14.
    Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, Refai W et al (1997) Chronic liver disease in the Alexandria Governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. J Hepatol 26:236–243PubMedCrossRefGoogle Scholar
  15. 15.
    Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS et al (2000) The role of parenteral antischistosomal therapy in the spread of hepatitis C in Egypt. Lancet 355:887–891PubMedCrossRefGoogle Scholar
  16. 16.
    Morales JM, Campistol JM, Andres A, Rodicio JL (1998) Hepatitis C virus and renal transplantation. Curr Opin Nephrol Hypertens 7:177–183PubMedCrossRefGoogle Scholar
  17. 17.
    Vosnides GG (1997) Hepatitis C in renal transplantation. Nephrol Forum Kidney Int 52:843–861CrossRefGoogle Scholar
  18. 18.
    Gohar SA, Khalil RY, Elaish NM, Khedr EM, Ahmed MS (1995) Prevalence of antibodies to hepatitis C virus in hemodialysis patients and renal transplant recipients. J Egypt Public Health Assoc 70(5–6):465–484PubMedGoogle Scholar
  19. 19.
    Zylberberg H, Nalpas B, Carnot F et al (2002) Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transpl 17:129–133CrossRefGoogle Scholar
  20. 20.
    Fehr T, Riehl HM, Nigg L et al (2003) Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters. Am J Kidney Dis 42:193–201PubMedCrossRefGoogle Scholar
  21. 21.
    Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M (2003) Combined interferon alpha2b and cyclosporine A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 38:567–572PubMedGoogle Scholar
  22. 22.
    Rostaing L, Izopet J, Cisterne JM, Arnaud C, Duffaut M, Rumeau JL, Puel J, Durand D (1998) Impact of hepatitis C virus duration and hepatitis C virus genotypes on renal transplant patients: correlation with clinicopathological features. Transplantation 65(7):930–936PubMedCrossRefGoogle Scholar
  23. 23.
    Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K (2003) Cyclosporine A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282–1288PubMedCrossRefGoogle Scholar
  24. 24.
    Nakagawa M, Sakamoto N, Enomoto N et al (2004) Specific inhibition of hepatitis C virus replication by cyclosporine A. Biochem Biophys Res Commun 313:42–47PubMedCrossRefGoogle Scholar
  25. 25.
    Tong MJ, El-Farra NS, Reikes AR et al (1995) Clinical outcomes after transfusion-associated hepatitis C. N Eng J Med 332:1463–1466CrossRefGoogle Scholar
  26. 26.
    Kiyosawa K, Sodeyama T, Tanaka E et al (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocelular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12:671–675PubMedCrossRefGoogle Scholar
  27. 27.
    Briggs Douglas (2001) Causes of death after renal transplantation. Nephrol Dial Transpl 16(8):1545–1549CrossRefGoogle Scholar
  28. 28.
    Seeff LB (1997) Natural history of hepatitis C. Hepatology 26(Suppl 1):21S–28SPubMedCrossRefGoogle Scholar
  29. 29.
    Pereira BJ, Natov SN, Bouthot BA et al (1998) Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ bank hepatitis C study group. Kidney Int 53:1374–1381PubMedCrossRefGoogle Scholar
  30. 30.
    Morales JM, Dominguez-Gil B, Sanz-Guajardo D et al (2004) The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transpl 19:72–76CrossRefGoogle Scholar
  31. 31.
    Fabrizi F, Martin P, Dixit V et al (2005) Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transpl 5:1452–1461CrossRefGoogle Scholar
  32. 32.
    Bruchfeld A, Wilczek H, Elinder CG (2004) Hepatitis C infection, time in renal-replacement therapy and outcome after kidney transplantation. Transplantation 78:745–750PubMedCrossRefGoogle Scholar
  33. 33.
    Gloor J, Sethi S, Stegall MD et al (2007) Transplant glomerulopathy subclinical incidence and association with alloantibody. Am J Transpl 7:2124–2132CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • A. R. Soliman
    • 1
  • A. Fathy
    • 1
  • S. Khashab
    • 1
  • N. Shaheen
    • 2
  1. 1.Department of NephrologyCairo UniversityCairoEgypt
  2. 2.Department of Clinical PathologyCairo UniversityCairoEgypt

Personalised recommendations